Equities

Nectar Lifesciences Ltd

NECLIFE:NSI

Nectar Lifesciences Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)42.25
  • Today's Change-1.70 / -3.87%
  • Shares traded3.64m
  • 1 Year change+67.99%
  • Beta1.1154
Data delayed at least 15 minutes, as of Sep 20 2024 11:29 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments203179162
Total Receivables, Net4,8224,4506,107
Total Inventory7,7657,3157,213
Prepaid expenses------
Other current assets, total4836866
Total current assets12,83812,31213,548
Property, plant & equipment, net6,5616,9047,652
Goodwill, net------
Intangibles, net524493430
Long term investments2.352.352.35
Note receivable - long term9873123
Other long term assets1,8131,9012,125
Total assets21,91121,89223,908
LIABILITIES
Accounts payable4,1973,1883,767
Accrued expenses1146587
Notes payable/short-term debt4,1224,5895,028
Current portion long-term debt/capital leases830684661
Other current liabilities, total466383497
Total current liabilities9,7288,90910,038
Total long term debt1,4032,2652,911
Total debt6,3557,5388,599
Deferred income tax------
Minority interest------
Other liabilities, total877280
Total liabilities11,21811,24613,029
SHAREHOLDERS EQUITY
Common stock224224224
Additional paid-in capital3,2883,2883,288
Retained earnings (accumulated deficit)7,1807,0917,367
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total--43--
Total equity10,69210,64610,879
Total liabilities & shareholders' equity21,91121,89223,908
Total common shares outstanding224224224
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.